{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:40Z","timestamp":1792787260283,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"https:\/\/ror.org\/02b3zmq47","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poor persistence and adherence to attention-deficit\/hyperactivity disorder (ADHD) medication is a significant barrier to effective long-term care, particularly during adolescence, yet age-specific and sex-specific trajectories remain poorly characterised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterise medication initiation, discontinuation and long-term adherence patterns for children and adolescents diagnosed with ADHD in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A nationwide retrospective cohort study, including 8961 children and adolescents (aged &lt;18 years) with a new ADHD diagnosis in child and adolescent mental health services between 1 January 2010 and 31 December 2012, with follow-up until 31 December 2021. Main outcomes were medication initiation rates; time to first medication discontinuation, analysed using Kaplan-Meier estimates and restricted mean survival time at 1 year and longitudinal adherence, measured by the proportion of days covered over 9 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Of the 8961 individuals in the cohort (mean age at diagnosis, 12 years; 69% male), 6661 (74.3%) initiated medication, with a median time from diagnosis to initiation of 106 days (IQR 17\u2013231); 55% initiated within 90 days. Discontinuation increased significantly with age; adolescents aged 15\u201317 years remained on treatment for 31.9 fewer days (95%\u2009CI \u221240.8 to \u221223.1; p&lt;0.001) in the first year compared with children aged 5\u201311 years. Females also discontinued significantly earlier than males (difference \u221213.2\u2009days; 95%\u2009CI \u221219.8 to \u22126.5; p&lt;0.001). Longitudinal analysis confirmed that older age at initiation and female sex were associated with a significantly steeper decline in medication coverage over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Discontinuation and low adherence to ADHD medication were common and increased substantially through adolescence, with females at higher risk of early cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Late adolescence warrants closer clinical monitoring and shared decision-making to support appropriate treatment continuation or well-informed discontinuation, particularly for older adolescents and females. Integrating structured transition planning and attention to sex-specific barriers may help reduce avoidable non-adherence during this high-risk period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2026-302649","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:20:18Z","timestamp":1782145218000},"page":"e302649","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["ADHD medication discontinuation and non-adherence: a Norwegian population-based register study"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-2330","authenticated-orcid":false,"given":"Miguel","family":"Garcia-Argibay","sequence":"first","affiliation":[{"name":"Centre for Population Health, Research Department, Division of Mental Health, Haukeland University Hospital, Bergen, Norway"},{"name":"Developmental EPI (Evidence synthesis, Prediction, Implementation) lab, Centre for Innovation in Mental Health, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK"},{"name":"School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Hofstad","sequence":"additional","affiliation":[{"name":"Centre for Population Health, Research Department, Division of Mental Health, Haukeland University Hospital, Bergen, Norway"},{"name":"Centre for Medical Ethics, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvar","family":"Bjelland","sequence":"additional","affiliation":[{"name":"Centre for Population Health, Research Department, Division of Mental Health, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-8075","authenticated-orcid":false,"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[{"name":"Developmental EPI (Evidence synthesis, Prediction, Implementation) lab, Centre for Innovation in Mental Health, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK"},{"name":"Hampshire and Isle of Wight NHS Foundation Trust, Southampton, UK"},{"name":"Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK"},{"name":"Hassenfeld Children\u2019s Hospital at NYU Langone, New York University Child Study Center, New York, New York, USA"},{"name":"DiMePRe-J-Department of Precision and Regenerative Medicine-Jonic Area, University of Bari \"Aldo Moro\", Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-0079","authenticated-orcid":false,"given":"Arnstein","family":"Mykletun","sequence":"additional","affiliation":[{"name":"Centre for Population Health, Research Department, Division of Mental Health, Haukeland University Hospital, Bergen, Norway"},{"name":"Centre for Work and Mental Health, Nordland Hospital Trust, Bod\u00f8, Norway"},{"name":"Department of Community Medicine, The Arctic University of Norway, Troms\u00f8, Norway"},{"name":"Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026091806103265000_29.1.e302649.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.01.022"},{"key":"2026091806103265000_29.1.e302649.2","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2023.2451","article-title":"A systematic meta-review of systematic reviews on attention deficit hyperactivity disorder","volume":"66","author":"Chaulagain","year":"2023","journal-title":"Eur Psychiatry"},{"key":"2026091806103265000_29.1.e302649.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1917069"},{"key":"2026091806103265000_29.1.e302649.4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2026091806103265000_29.1.e302649.5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18111296"},{"key":"2026091806103265000_29.1.e302649.6","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001131"},{"key":"2026091806103265000_29.1.e302649.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083658","article-title":"ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials","volume":"390","author":"Zhang","year":"2025","journal-title":"BMJ"},{"key":"2026091806103265000_29.1.e302649.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.07.016"},{"key":"2026091806103265000_29.1.e302649.9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaac.2023.05.025","article-title":"Effect of Pharmacological Treatment of Attention-Deficit\/Hyperactivity Disorder on Criminality","volume":"63","author":"Widding-Havneraas","year":"2024","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2026091806103265000_29.1.e302649.10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S2215-0366(23)00332-2","article-title":"ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases","volume":"11","author":"Brikell","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2026091806103265000_29.1.e302649.11","article-title":"A review of attention-deficit\/hyperactivity disorder in women and girls: uncovering this hidden diagnosis","volume":"16","author":"Quinn","year":"2014","journal-title":"Prim Care Companion CNS Disord"},{"key":"2026091806103265000_29.1.e302649.12","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5490"},{"key":"2026091806103265000_29.1.e302649.13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S2215-0366(24)00396-1","article-title":"Evaluating ADHD medication trial representativeness: a Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individuals","volume":"12","author":"Garcia-Argibay","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026091806103265000_29.1.e302649.14","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2022.0061"},{"key":"2026091806103265000_29.1.e302649.15","first-page":"1543","article-title":"Adherence, persistence, and medication discontinuation in patients with attention-deficit\/hyperactivity disorder - a systematic literature review","volume":"10","author":"Gajria","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026091806103265000_29.1.e302649.16","doi-asserted-by":"crossref","DOI":"10.1186\/s40545-021-00385-w","article-title":"Estimating proportion of days covered (PDC) using real-world online medicine suppliers\u2019 datasets","volume":"14","author":"Prieto-Merino","year":"2021","journal-title":"J Pharm Policy Pract"},{"key":"2026091806103265000_29.1.e302649.17","unstructured":"R Core Team . R: a language and environment for statistical computing. 2023. Available: https:\/\/www.R-project.org\/"},{"key":"2026091806103265000_29.1.e302649.18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13632752.2019.1582762","article-title":"Adolescent experiences of living with a diagnosis of ADHD: a systematic review and thematic synthesis","volume":"24","author":"Eccleston","year":"2019","journal-title":"Emot Behav Difficulties"},{"key":"2026091806103265000_29.1.e302649.19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/hex.13031","article-title":"Exploring factors influencing initiation, implementation and discontinuation of medications in adults with ADHD","volume":"24 Suppl 1","author":"Khan","year":"2021","journal-title":"Health Expect"},{"key":"2026091806103265000_29.1.e302649.20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.acap.2017.09.005","article-title":"Reasons Why Children and Adolescents With Attention-Deficit\/Hyperactivity Disorder Stop and Restart Taking Medicine","volume":"18","author":"Brinkman","year":"2018","journal-title":"Acad Pediatr"},{"key":"2026091806103265000_29.1.e302649.21","doi-asserted-by":"publisher","DOI":"10.1111\/cch.12978"},{"key":"2026091806103265000_29.1.e302649.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1390-7"},{"key":"2026091806103265000_29.1.e302649.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-024-06199-9","article-title":"Nationwide trends in the use of ADHD medications in the period 2006-2022: a study from the Norwegian prescription database","volume":"24","author":"Hartz","year":"2024","journal-title":"BMC Psychiatry"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2026-302649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:10:56Z","timestamp":1789737056000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2026-302649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjment-2026-302649"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2026-302649","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}